zavante.com valuation and analysis
Robots.txt Information
| Robot | Path | Permission |
| GoogleBot | / | ✔ |
| BingBot | / | ✔ |
| BaiduSpider | / | ✔ |
| YandexBot | / | ✔ |
Meta Tags
| Title | Commercial Stage Biopharmaceutical Company | |
| Description | Driven to Deliver Innovative Treatments for Patients With Infectious Nabriva is a commercial-stage biopharmaceutical company engaged in the research & development of novel antibiotics to treat serious infections, with a current focus on the pleuromutilin class of antibiotics. Learn more at |
| Keywords | Commercial stage biopharmaceutical company, medications for infectious diseases, new antibiotics |
Server Information
| WebSite | |
| Host IP | 165.160.13.20 |
| Location | United States |
Related Websites
| Site | Rank |
More to Explore
zavante.com Valuation
|
US$1,737
Last updated: 2023-05-14 04:15:02
zavante.com has Semrush global rank of 0. zavante.com has an estimated worth of US$ 1,737, based on its estimated Ads revenue. zavante.com receives approximately 200 unique visitors each day. Its web server is located in United States, with IP address 165.160.13.20. According to SiteAdvisor, zavante.com is safe to visit. |
Traffic & Worth Estimates
| Purchase/Sale Value | US$1,737 |
| Daily Ads Revenue | US$1 |
| Monthly Ads Revenue | US$48 |
| Yearly Ads Revenue | US$577 |
| Daily Unique Visitors | 13 |
| Note: All traffic and earnings values are estimates. | |
DNS Records
| Host | Type | TTL | Data |
| zavante.com. | A | 14400 | IP: 165.160.13.20 |
| zavante.com. | A | 14400 | IP: 165.160.15.20 |
| zavante.com. | NS | 14400 | NS Record: dns1.cscdns.net. |
| zavante.com. | NS | 14400 | NS Record: dns2.cscdns.net. |
| zavante.com. | MX | 300 | MX Record: 10 eu-smtp-inbound-2.mimecast.com. |
| zavante.com. | MX | 300 | MX Record: 10 eu-smtp-inbound-1.mimecast.com. |
| zavante.com. | TXT | 300 | TXT Record: 0ed1fe018ac0083a0cea314f9782acb9e2a87e1b62 |
| zavante.com. | TXT | 300 | TXT Record: MS=ms50869710 |
| zavante.com. | TXT | 300 | TXT Record: MS=ms65886593 |
| zavante.com. | TXT | 300 | TXT Record: b9lgm8h8v1qaqtil0ff7frvi2o |
| zavante.com. | TXT | 300 | TXT Record: google-site-verification=d0NmokIMv5pOV6bKBjfzDzTdoo8hgcgXSNKmD3aatpk |
| zavante.com. | TXT | 300 | TXT Record: nabcorp01.azurewebsites.net |
| zavante.com. | TXT | 3600 | TXT Record: v=spf1 include:_netblocks.mimecast.com include:email.freshservice.com -all |
HtmlToTextCheckTime:2023-05-14 04:15:02
| Go to... Home About Nabriva Our Products Named Patient Program Meet the Team pipeline & research Fosfomycin pleuromutilins For Investors Events & Presentations Press Releases Financial Performance Share Performance Shareholder Information Corporate Governance News & Publications careers contact us Nabriva US News & Publications Careers Contact Us Home About Nabriva Our Products Named Patient Program Meet the Team pipeline & research Fosfomycin pleuromutilins For Investors Events & Presentations Press Releases Financial Performance Share Performance Shareholder Information Corporate Governance News & Publications careers contact us Site Web Search --> MEDICAL PROFESSIONALS - REGISTER NOW Click here to learn more about Xenleta™ (lefamulin) for both Oral and IV Use | FDA Approves Xenleta TM (lefamulin) for both Oral and IV Use ––> --> Driven to Deliver Innovative Treatments for Patients With Infectious Diseases Nabriva Therapeutics is a commercial-stage |
HTTP Headers
HTTP/1.1 301 Moved Permanently Date: Wed, 22 Dec 2021 18:17:21 GMT Location: https://www.nabriva.com Content-Length: 0 X-ORACLE-DMS-ECID: c478181d-3bb0-4d43-bbdf-1644a36102a3-5c82f757 X-ORACLE-DMS-RID: 0 HTTP/1.1 200 OK Cache-Control: public Content-Length: 34805 Content-Type: text/html; charset=utf-8 Set-Cookie: dnn_IsMobile=False; path=/; HttpOnly Set-Cookie: language=en-US; path=/; HttpOnly Set-Cookie: .ASPXANONYMOUS=dDUEVnP6SMgri1DAgqNEZt8xOZJVAtx7HV0-knkw-k7YfQNUu0qu8ThnkJ-ha9HSg5eZaQOUl5Fqgaw8s8idbH77uMYxrFnzq0gAf88ciLTu8UCA0; expires=Wed, 02-Mar-2022 04:57:21 GMT; path=/; HttpOnly Set-Cookie: __RequestVerificationToken=oLc7w6paNPMCiH11w0EDDYcK2jVgO0POfkEUOFvPixC8Jfus02tdJl42vREXeRGdTfqWYw2; path=/; HttpOnly X-UA-Compatible: IE=edge X-XSS-Protection: 1; mode=block X-Frame-Options: SAMEORIGIN Set-Cookie: ARRAffinity=8178b3b2e8d11c3c178adca749545f846d9882b742e0df864a4df01a5d808af5;Path=/;HttpOnly;Secure;Domain=www.nabriva.com Set-Cookie: ARRAffinitySameSite=8178b3b2e8d11c3c178adca749545f846d9882b742e0df864a4df01a5d808af5;Path=/;HttpOnly;SameSite=None;Secure;Domain=www.nabriva.com Date: Wed, 22 Dec 2021 18:17:21 GMT |
zavante.com Whois Information
Domain Name: ZAVANTE.COM Registry Domain ID: 20651566_DOMAIN_COM-VRSN Registrar WHOIS Server: whois.corporatedomains.com Registrar URL: http://cscdbs.com Updated Date: 2021-02-20T06:12:09Z Creation Date: 2000-02-25T00:34:09Z Registry Expiry Date: 2022-02-25T00:34:09Z Registrar: CSC Corporate Domains, Inc. Registrar IANA ID: 299 Registrar Abuse Contact Email: domainabuse@cscglobal.com Registrar Abuse Contact Phone: 8887802723 Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited Name Server: DNS1.CSCDNS.NET Name Server: DNS2.CSCDNS.NET DNSSEC: unsigned >>> Last update of whois database: 2021-12-25T08:16:07Z <<< |